Lirafit 6 mg/ml Prefilled Pen 3 ml belongs to the class of anti-diabetic drugs, primarily used to treat type 2 diabetes mellitus in the children above 10 years and adult. Diabetes mellitus is a metabolic disease that causes high blood sugar levels. Type 2 diabetes occurs when a hormone released by the pancreas to lower blood glucose called 'insulin' is secreted but unable to get utilized by our body's cell to produce energy.  

Lirafit 6 mg/ml Prefilled Pen 3 ml contains Liraglutide a recombinant Deoxyribonucleic acid (rDNA) which works by increasing insulin release from the pancreas during high blood sugar levels (after meal) and decreases the amount of sugar the liver makes. Lirafit 6 mg/ml Prefilled Pen 3 ml also slows stomach emptying time, thereby decreasing appetite and promotes weight loss in an individual. 

Some common side effects of Lirafit 6 mg/ml Prefilled Pen 3 ml include nausea, vomiting, diarrhoea, decreased appetite, stomach upset, constipation, headache, feeling tired, rash, and dizziness. These side effects are not familiar to everyone and vary individually. If you notice any side effects that are not manageable, please consult your doctor. 

Before starting Lirafit 6 mg/ml Prefilled Pen 3 ml, let your doctor know if you have any medical history of heart, kidney or liver diseases, pancreatitis (inflammation of the pancreas), and stomach disorders like gastroparesis (delayed gastric emptying). Do not take or stop this medicine, if the doctor did not advise you to do so. Do not concurrently use Lirafit 6 mg/ml Prefilled Pen 3 ml with prandial insulin (mealtime insulin). It is advised to limit your alcohol intake while using Lirafit 6 mg/ml Prefilled Pen 3 ml to avoid low blood sugar levels further. Pregnant and breastfeeding women should consult their doctor before starting Lirafit 6 mg/ml Prefilled Pen 3 ml.

Lirafit 6 mg/ml Prefilled Pen 3 ml treats type 2 diabetes mellitus and contains ‘Liraglutide’. It is a recombinant DNA (rDNA) that mimics the action of a natural hormone called Incretin (metabolic hormone, which stimulates a decrease in blood glucose levels). It works by increasing insulin release from the pancreas during high blood sugar levels (after meal) and decreases the amount of sugar the liver makes. Lirafit 6 mg/ml Prefilled Pen 3 ml may be advised with or without other medications along with diet and exercise to control blood sugar levels. 

Brief your medical history if you have any heart, kidney or liver diseases, pancreatitis (inflammation of the pancreas), stomach disorders like gastroparesis (delayed gastric emptying), high cholesterol levels, gallbladder problems, and depression before starting Lirafit 6 mg/ml Prefilled Pen 3 ml. Lirafit 6 mg/ml Prefilled Pen 3 ml is contraindicated in patients with multiple endocrine neoplasia type 2 (tumours in thyroid and parathyroid glands) and personal or family history of thyroid cancer. Do not concurrently use Lirafit 6 mg/ml Prefilled Pen 3 ml with prandial insulin (mealtime insulin). If you are also using insulin, take Lirafit 6 mg/ml Prefilled Pen 3 ml and insulin injections separately. Please do not mix them. You can inject both injections in the same body region, but the injection sites should not be next to each other. Do not share an injection pen, cartridge, or syringe with another person, even if the needle is changed. It is advised to limit your alcohol intake while using Lirafit 6 mg/ml Prefilled Pen 3 ml to avoid low blood sugar levels further. Pregnant and breastfeeding women should consult their doctor before starting this medication. Lirafit 6 mg/ml Prefilled Pen 3 ml is advised to be only used in children above ten years of age and adults.